Pre-close Statement

Hikma Pharmaceuticals Plc
13 July 2006



                              Pre-close statement

LONDON, 13 July 2006 - Hikma Pharmaceuticals PLC ('Hikma') (LSE: HIK) (DIFX:
HIK), the multinational pharmaceuticals group, will enter its close period on
Saturday 15 July 2006 ahead of its interim results announcement for the six
months ending 30 June 2006, to be made on 13 September 2006.

Since publishing its AGM trading statement on 25 May 2006, the Group has
continued to perform well.

On a segmental basis, we have seen a strong sales performance in the Branded
business. As anticipated, the new Algerian reference pricing regime has had an
impact on sales in Algeria in the first half, though this has been mostly offset
by a strong sales performance in other markets. We remain confident that we can
deliver growth in Algeria on a full-year basis. This, combined with new product
launches and increased penetration of new and existing markets, should
accelerate Branded sales growth in the second half of the year.

In the Injectables business we are continuing to deliver substantial growth in
the US, Europe and the MENA region. We expect to maintain this growth through
the second half of the year.

In the Generics business, our most competitive market, we are generating higher
sales volumes in an environment of continued pricing pressure. In the second
half of the year, we expect new product launches to drive revenue growth for the
year as a whole.

Overall, the Group remains on track to deliver strong growth for the full year.


                                    - ENDS -

Enquiries:

Hikma Pharmaceuticals PLC
Susan Ringdal                                         [phone]
Investor Relations Director

Brunswick Group
Jon Coles / Justine McIlroy / Alex Tweed              [phone]


About Hikma

Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the United States,
the Middle East and North Africa ('MENA') region and Europe. In 2005, the Group
had revenue of $262 million and profit attributable to shareholders of $44
million. At 31 December 2005, the Group had over 1,800 employees. For news and
other information, please visit www.hikma.com.



                      This information is provided by RNS
            The company news service from the London Stock Exchange